Nothing lasts forever. Especially in the world of drug development. A new medication from the drug company Eli Lilly called Tirzepatide will be seeking FDA approval for diabetes management in 2022, and I suspect it will be seeking approval for obesity management shortly thereafter. Trials have been completed, and tirzepatide has been shown to have some very remarkable results not only in managing blood sugars but also in weight-loss. Let’s take a look at the results and see if the King will still be standing!